LEADING WITH HEART – The Women of PHKL Shaping the Future of Healthcare
KUALA LUMPUR, Malaysia, March 7, 2025 /PRNewswire/ -- Healthcare is more than science—it is compassion, resilience, and an unwavering commitment to healing. Behind every life saved and every family given hope, there are extraordinary individuals who dedicate themselves to the well-being of others. This International Women's Day, Pantai Hospital Kuala Lumpur (PHKL) honours the women who do just that—exceptional doctors...
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small...
THE BRACCO GROUP: OFFICIAL GOLD SPONSOR OF THE ITALY PAVILION AT THE OSAKA EXPO 2025
At the Japanese World Expo, to be held from April 13 to October 13, 2025, the Bracco Group will be a key contributor on the themes of art, technology and medicine of the future. In addition to several scientific events organized by Bracco Japan, a ballet by the La Scala Academy on...
NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere ‘Nexsphere-F™’
Pioneering a Paradigm Shift in Pain Treatment, Accelerating Global Market Expansion SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable microsphere for musculoskeletal pain embolization, has received the Breakthrough Device Designation from the U.S. Food and...
Lunit Expands Partnership with Saudi Arabia’s Largest Medical Group to Deploy AI Chest X-Ray Solution
Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a second agreement with Cloud...
GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy
SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X, a first-in-class base editing drug for Duchenne Muscular Dystrophy (DMD). GenAssist...
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability. Preclinical data also showed...
HKIAAC – At the forefront of the international anti-corruption cause
HONG KONG, March 6, 2025 /PRNewswire/ -- The Hong Kong International Academy Against Corruption (HKIAAC), established by the Hong Kong Independent Commission Against Corruption (ICAC) in February 2024 to spearhead both local and international anti-corruption training initiatives and experience sharing, is stepping into its second year with reaffirmed commitment.   The HKIAAC, with the full support of...
Docquity’s AI Platform Enhances Medical Knowledge and Patient Care at RSUD Umar Wirahadikusumah Sumedang
Dx, Docquity's AI platform which is in ongoing development, will enable physicians at the Sumedang hospital to securely access the latest medical research for stronger treatment decisions The collaboration follows Sumedang Regency's introduction of Docquity's AI platform for greater public health support last year JAKARTA, Indonesia, March 6, 2025 /PRNewswire/...
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
HONG KONG, March 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following...
